journal
Journals CA: a Cancer Journal for Clini...

CA: a Cancer Journal for Clinicians

https://read.qxmd.com/read/39207233/overlooked-barriers-to-implementation-of-geriatric-assessment
#1
EDITORIAL
Banu E Symington, Paul G Montgomery
No abstract text is available yet for this article.
August 29, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/39207229/geriatric-assessment-for-the-practicing-clinician-the-why-what-and-how
#2
REVIEW
Allison Magnuson, Kah Poh Loh, Fiona Stauffer, William Dale, Nikesha Gilmore, Sindhuja Kadambi, Heidi D Klepin, Kaitlin Kyi, Lisa M Lowenstein, Tanyanika Phillips, Erika Ramsdale, Melody K Schiaffino, John F Simmons, Grant R Williams, Jason Zittel, Supriya Mohile
Older adults with cancer heterogeneously experience health care, treatment, and symptoms. Geriatric assessment (GA) offers a comprehensive evaluation of an older individual's health status and can predict cancer-related outcomes in individuals with solid tumors and those with hematologic malignancies. In the last decade, randomized controlled trials have demonstrated the benefits of GA and GA management (GAM), which uses GA information to provide tailored intervention strategies to address GA impairments (e...
August 29, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38990124/proportion-and-number-of-cancer-cases-and-deaths-attributable-to-potentially-modifiable-risk-factors-in-the-united-states-2019
#3
JOURNAL ARTICLE
Farhad Islami, Emily C Marlow, Blake Thomson, Marjorie L McCullough, Harriet Rumgay, Susan M Gapstur, Alpa V Patel, Isabelle Soerjomataram, Ahmedin Jemal
In 2018, the authors reported estimates of the number and proportion of cancers attributable to potentially modifiable risk factors in 2014 in the United States. These data are useful for advocating for and informing cancer prevention and control. Herein, based on up-to-date relative risk and cancer occurrence data, the authors estimated the proportion and number of invasive cancer cases (excluding nonmelanoma skin cancers) and deaths, overall and for 30 cancer types among adults who were aged 30 years and older in 2019 in the United States, that were attributable to potentially modifiable risk factors...
July 11, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38896503/cancer-misinformation-on-social-media
#4
REVIEW
Stacy Loeb, Aisha T Langford, Marie A Bragg, Robert Sherman, June M Chan
Social media is widely used globally by patients, families of patients, health professionals, scientists, and other stakeholders who seek and share information related to cancer. Despite many benefits of social media for cancer care and research, there is also a substantial risk of exposure to misinformation, or inaccurate information about cancer. Types of misinformation vary from inaccurate information about cancer risk factors or unproven treatment options to conspiracy theories and public relations articles or advertisements appearing as reliable medical content...
June 19, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38814103/the-evolving-landscape-of-tissue-agnostic-therapies-in-precision-oncology
#5
REVIEW
Vivek Subbiah, Mohamed A Gouda, Bettina Ryll, Howard A Burris, Razelle Kurzrock
Tumor-agnostic therapies represent a paradigm shift in oncology by altering the traditional means of characterizing tumors based on their origin or location. Instead, they zero in on specific genetic anomalies responsible for fueling malignant growth. The watershed moment for tumor-agnostic therapies arrived in 2017, with the US Food and Drug Administration's historic approval of pembrolizumab, an immune checkpoint inhibitor. This milestone marked the marriage of genomics and immunology fields, as an immunotherapeutic agent gained approval based on genomic biomarkers, specifically, microsatellite instability-high or mismatch repair deficiency (dMMR)...
May 30, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38703384/evolution-of-community-outreach-and-engagement-at-national-cancer-institute-designated-cancer-centers-an-evolving-journey
#6
REVIEW
Sarah A Pohl, Barry A Nelson, Tanjeena R Patwary, Salina Amanuel, Edward J Benz, Christopher S Lathan
Cancer mortality rates have declined during the last 28 years, but that process is not equitably shared. Disparities in cancer outcomes by race, ethnicity, socioeconomic status, sexual orientation and gender identity, and geographic location persist across the cancer care continuum. Consequently, community outreach and engagement (COE) efforts within National Cancer Institute-Designated Cancer Center (NCI-DCC) catchment areas have intensified during the last 10 years as has the emphasis on COE and catchment areas in NCI's Cancer Center Support Grant applications...
May 4, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38685134/critical-updates-in-neuroendocrine-tumors-version-9-american-joint-committee-on-cancer-staging-system-for-gastroenteropancreatic-neuroendocrine-tumors
#7
JOURNAL ARTICLE
Aman Chauhan, Kelley Chan, Thorvardur R Halfdanarson, Andrew M Bellizzi, Guido Rindi, Dermot O'Toole, Phillip S Ge, Dhanpat Jain, Arvind Dasari, Daniel A Anaya, Emily Bergsland, Erik Mittra, Alice C Wei, Thomas A Hope, Ayse T Kendi, Samantha M Thomas, Sherlonda Flem, James Brierley, Elliot A Asare, Kay Washington, Chanjuan Shi
The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma...
April 29, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38652221/cancer-diagnosis-and-treatment-in-working-age-adults-implications-for-employment-health-insurance-coverage-and%C3%A2-financial-hardship-in-the-united-states
#8
JOURNAL ARTICLE
K Robin Yabroff, Joanna F Doran, Jingxuan Zhao, Fumiko Chino, Ya-Chen Tina Shih, Xuesong Han, Zhiyuan Zheng, Cathy J Bradley, Monica F Bryant
The rising costs of cancer care and subsequent medical financial hardship for cancer survivors and families are well documented in the United States. Less attention has been paid to employment disruptions and loss of household income after a cancer diagnosis and during treatment, potentially resulting in lasting financial hardship, particularly for working-age adults not yet age-eligible for Medicare coverage and their families. In this article, the authors use a composite patient case to illustrate the adverse consequences of cancer diagnosis and treatment for employment, health insurance coverage, household income, and other aspects of financial hardship...
April 23, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38572751/global-cancer-statistics-2022-globocan-estimates-of-incidence-and-mortality-worldwide-for-36-cancers-in-185-countries
#9
JOURNAL ARTICLE
Freddie Bray, Mathieu Laversanne, Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Isabelle Soerjomataram, Ahmedin Jemal
This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC). There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2...
April 4, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38517471/multicancer-detection-tests-what-we-know-and-what-we-don-t-know
#10
EDITORIAL
Sam M Hanash, Peter P Yu
No abstract text is available yet for this article.
March 22, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38363123/erratum-to-cancer-statistics-2024
#11
(no author information available yet)
No abstract text is available yet for this article.
February 16, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38329372/neoadjuvant-chemotherapy-for-advanced-oral-cavity-cancer
#12
JOURNAL ARTICLE
Dan Yaniv, Tanguy Y Seiwert, Danielle N Margalit, Michelle D Williams, Carly E A Barbon, Rene D Largo, Jon A Smith, Neil D Gross
No abstract text is available yet for this article.
February 8, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38230825/cancer-statistics-2024-all-hands-on-deck
#13
EDITORIAL
Don S Dizon, Arif H Kamal
No abstract text is available yet for this article.
January 17, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38230766/cancer-statistics-2024
#14
JOURNAL ARTICLE
Rebecca L Siegel, Angela N Giaquinto, Ahmedin Jemal
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2020) and mortality data collected by the National Center for Health Statistics (through 2021). In 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both the adjuvant and metastatic settings...
January 17, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/39223442/osimertinib-prolongs-progression-free-lung-cancer-survival-after-chemotherapy
#15
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/39223440/cancer-disparities-for-lgbtq-patients-identified-more-fully
#16
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38965742/colon-cancer-blood-test-effective-for-average-risk-population
#17
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38965740/key-issues-face-ai-deployment-in-cancer-care
#18
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38720557/the-association-between-menopausal-hormone-therapy-and-breast-cancer-remains-unsettled
#19
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38720549/better-communication-is-key-for-quality-of-life-improvement-in-low-income-and-minority-patients
#20
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
journal
journal
20065
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.